Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$1.45 +1.4%	$1.57	$1.13 ▼ $2.66	$127.61M	2.61	202,675 shs	150,805 shs
CTOR Citius Oncology	$1.75 +7.4%	$2.46	$0.55 ▼ $6.19	$127.74M	3	468,200 shs	281,705 shs
FGEN FibroGen	$11.18 +0.8%	$7.29	$4.50 ▼ $21.94	$44.85M	0.76	68,852 shs	33,477 shs
KYTX Kyverna Therapeutics	$3.85 +7.5%	$3.46	$1.78 ▼ $8.78	$154.82M	3.05	259,877 shs	632,566 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	-0.69%	-1.38%	-7.74%	-1.38%	-27.41%
CTOR Citius Oncology	+1.24%	-5.23%	-1.21%	+79.12%	-15.54%
FGEN FibroGen	+4.43%	+16.98%	+43.84%	+34.42%	+10.60%
KYTX Kyverna Therapeutics	+4.37%	+1.13%	-12.68%	+57.71%	-57.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEN Compugen	2.0235 of 5 stars	3.5	3.0	0.0	2.6	0.0	0.0
CTOR Citius Oncology	1.6543 of 5 stars	3.0	0.0	0.0	2.6	1.7	0.0
FGEN FibroGen	4.6454 of 5 stars	3.3	5.0	4.7	2.2	3.3	0.6
KYTX Kyverna Therapeutics	2.7572 of 5 stars	3.6	2.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$4.00	175.86% Upside
CTOR Citius Oncology	2.00	Hold	$3.00	71.43% Upside
FGEN FibroGen	2.50	Moderate Buy	$43.00	284.62% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$15.60	305.19% Upside

Current Analyst Ratings Breakdown

Latest FGEN, CTOR, KYTX, and CGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	KYTX Kyverna Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
8/7/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$43.00
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/23/2025	CTOR Citius Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/23/2025	CTOR Citius Oncology	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$27.86M	4.64	N/A	N/A	$0.56 per share	2.59
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.41 per share	N/A
FGEN FibroGen	$29.62M	1.52	N/A	N/A	($50.08) per share	-0.22
KYTX Kyverna Therapeutics	$7.03M	23.69	N/A	N/A	$4.26 per share	0.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	-$14.23M	-$0.22	N/A	N/A	N/A	-87.45%	-34.77%	-16.82%	N/A
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-51.93%	-22.17%	N/A
FGEN FibroGen	-$47.58M	-$0.38	N/A	N/A	N/A	-3.86%	N/A	-27.34%	N/A
KYTX Kyverna Therapeutics	-$127.48M	-$3.68	N/A	N/A	N/A	N/A	-64.98%	-56.17%	N/A

Latest FGEN, CTOR, KYTX, and CGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	KYTX Kyverna Therapeutics	-$1.00	-$0.97	+$0.03	-$0.97	N/A	N/A
8/11/2025	Q2 2025	FGEN FibroGen	-$2.25	-$3.38	-$1.13	-$1.88	$2.88 million	$1.30 million
8/6/2025	Q2 2025	CGEN Compugen	-$0.07	-$0.08	-$0.01	-$0.08	$3.95 million	$1.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	4.74	4.74
CTOR Citius Oncology	0.12	0.35	0.02
FGEN FibroGen	N/A	1.04	1.02
KYTX Kyverna Therapeutics	N/A	5.39	5.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
CTOR Citius Oncology	70.52%
FGEN FibroGen	72.71%
KYTX Kyverna Therapeutics	18.08%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
CTOR Citius Oncology	4.57%
FGEN FibroGen	3.07%
KYTX Kyverna Therapeutics	22.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
CTOR Citius Oncology	N/A	78.37 million	74.79 million	N/A
FGEN FibroGen	570	4.04 million	3.92 million	Optionable
KYTX Kyverna Therapeutics	96	43.25 million	33.73 million	Optionable

FGEN, CTOR, KYTX, and CGEN Headlines

Recent News About These Companies

Kyverna Therapeutics (NASDAQ:KYTX) Now Covered by William Blair

August 22 at 9:16 AM | marketbeat.com

Here's Why Kyverna Therapeutics (NASDAQ:KYTX) Must Use Its Cash Wisely

August 21 at 8:29 AM | finance.yahoo.com

William Blair Initiates Coverage of Kyverna Therapeutics (KYTX) with Outperform Recommendation

August 21 at 3:28 AM | msn.com

Kyverna Therapeutics initiated with an Outperform at William Blair

August 20 at 4:59 PM | msn.com

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

August 20 at 3:29 PM | benzinga.com

Kyverna Therapeutics: Promising Potential in Immune Cell Therapies with KYV-101

August 20 at 5:51 AM | tipranks.com

Research Analysts Set Expectations for KYTX FY2025 Earnings

August 17, 2025 | marketbeat.com

Leerink Partnrs Analysts Reduce Earnings Estimates for KYTX

August 17, 2025 | marketbeat.com

Leerink Partnrs Issues Negative Outlook for KYTX Earnings

August 17, 2025 | americanbankingnews.com

Kyverna Therapeutics (NASDAQ:KYTX) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

August 14, 2025 | marketbeat.com

Kyverna Therapeutics, Inc.: Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 13, 2025 | finanznachrichten.de

Kyverna Therapeutics reports Q2 EPS (97c), consensus ($1.04)

August 12, 2025 | msn.com

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 12, 2025 | globenewswire.com

Kyverna Therapeutics (KYTX) Expected to Announce Earnings on Monday

August 5, 2025 | marketbeat.com

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Buy" from Brokerages

August 4, 2025 | marketbeat.com

Kyverna Appoints New CFO to Guide Next Growth Phase

July 29, 2025 | msn.com

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

July 29, 2025 | prnewswire.com

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 2, 2025 | globenewswire.com

Kyverna Therapeutics Names Marc Grasso Chief Financial Officer

June 30, 2025 | marketwatch.com

Kyverna Therapeutics Announces Appointment of New Chief Financial Officer

June 30, 2025 | finance.yahoo.com

Kyverna Therapeutics (NASDAQ:KYTX) Activity Grows on Nasdaq Composite, Russell 1000

June 27, 2025 | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

FGEN, CTOR, KYTX, and CGEN Company Descriptions

Compugen NASDAQ:CGEN

$1.45 +0.02 (+1.40%)

Closing price 04:00 PM Eastern

Extended Trading

$1.54 +0.09 (+6.21%)

As of 07:07 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Citius Oncology NASDAQ:CTOR

$1.75 +0.12 (+7.36%)

Closing price 04:00 PM Eastern

Extended Trading

$1.72 -0.03 (-2.00%)

As of 07:54 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

FibroGen NASDAQ:FGEN

$11.18 +0.09 (+0.81%)

Closing price 04:00 PM Eastern

Extended Trading

$11.14 -0.04 (-0.40%)

As of 07:57 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Kyverna Therapeutics NASDAQ:KYTX

$3.85 +0.27 (+7.54%)

Closing price 04:00 PM Eastern

Extended Trading

$3.92 +0.07 (+1.79%)

As of 07:54 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time